Stakeholder feedback
Novo Nordisk values stakeholders’ review of the company's reporting and welcomes any questions or comments concerning the report or the company’s performance. Send an email or get in touch.
We recognise that reporting is but one element of our communication with stakeholders. The objective of reporting is to enhance stakeholders’ valuation of the company, be it financially or in terms of reputation and trust.
Reader survey
Following the publication in February 2005 of the Annual Report 2004, Novo Nordisk will conduct a survey among shareholders and other readers of the report to solicit their reactions to the information conveyed through the report and to help assess whether and how this may affect their views on the company’s performance and its position for the future.
See a summary of the survey results.
Independendt studies
In addition, Novo Nordisk will commission independent studies of the report, with particular focus on assessing the value of integrated reporting as a means of enhancing accountability to stakeholders.
Exploring the boundaries
There are obvious benefits associated with integrated reporting, but also challenges. And there are dilemmas that remain to be reconciled. For instance:
- How to report on all issues considered material to diverse stakeholders and yet maintain a readable and manageable reporting format?
- How to be accountable to shareholders, in compliance with current regulatory framework, and yet maintain other stakeholders’ information needs?
- How to report in accordance with legal requirements and voluntary standards and yet continue to innovate communication with stakeholders through the report format?
Novo Nordisk will continue to take part in the development of reporting and corporate accountability as an active voice in the debate.
Share your views
During 2005, Novo Nordisk will continue to develop the materiality criteria for reporting. In this respect, and in order to continually improve performance and communication, stakeholder engagement and feedback is invaluable.
Send an email if you want to share your views on how Novo Nordisk’s reporting can improve in terms of materiality, completeness and responsiveness.
Key points, suggestions and frequently asked questions will be communicated here.
